JP2019537596A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537596A5
JP2019537596A5 JP2019523672A JP2019523672A JP2019537596A5 JP 2019537596 A5 JP2019537596 A5 JP 2019537596A5 JP 2019523672 A JP2019523672 A JP 2019523672A JP 2019523672 A JP2019523672 A JP 2019523672A JP 2019537596 A5 JP2019537596 A5 JP 2019537596A5
Authority
JP
Japan
Prior art keywords
theta
hexafluoropropan
trifluoromethyl
benzyl
carboxylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523672A
Other languages
English (en)
Japanese (ja)
Other versions
JP7042548B2 (ja
JP2019537596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061875 external-priority patent/WO2018093953A1/en
Publication of JP2019537596A publication Critical patent/JP2019537596A/ja
Publication of JP2019537596A5 publication Critical patent/JP2019537596A5/ja
Priority to JP2022035398A priority Critical patent/JP7350117B2/ja
Application granted granted Critical
Publication of JP7042548B2 publication Critical patent/JP7042548B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523672A 2016-11-16 2017-11-15 Magl阻害剤の結晶形態 Expired - Fee Related JP7042548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035398A JP7350117B2 (ja) 2016-11-16 2022-03-08 Magl阻害剤の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035398A Division JP7350117B2 (ja) 2016-11-16 2022-03-08 Magl阻害剤の結晶形態

Publications (3)

Publication Number Publication Date
JP2019537596A JP2019537596A (ja) 2019-12-26
JP2019537596A5 true JP2019537596A5 (cg-RX-API-DMAC7.html) 2020-12-24
JP7042548B2 JP7042548B2 (ja) 2022-03-28

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523672A Expired - Fee Related JP7042548B2 (ja) 2016-11-16 2017-11-15 Magl阻害剤の結晶形態
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Magl阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Magl阻害剤の結晶形態

Country Status (38)

Country Link
US (2) US11142517B2 (cg-RX-API-DMAC7.html)
EP (2) EP3541807B1 (cg-RX-API-DMAC7.html)
JP (2) JP7042548B2 (cg-RX-API-DMAC7.html)
KR (1) KR102508739B1 (cg-RX-API-DMAC7.html)
CN (2) CN115093382A (cg-RX-API-DMAC7.html)
AU (1) AU2017361257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019010003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043610A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001340A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019005045A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190242A (cg-RX-API-DMAC7.html)
CY (2) CY1124870T1 (cg-RX-API-DMAC7.html)
DK (1) DK3541807T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000120A (cg-RX-API-DMAC7.html)
EA (1) EA201991086A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19035171A (cg-RX-API-DMAC7.html)
ES (2) ES2966939T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20237559B (cg-RX-API-DMAC7.html)
HR (2) HRP20231697T1 (cg-RX-API-DMAC7.html)
HU (2) HUE064559T2 (cg-RX-API-DMAC7.html)
IL (1) IL266548A (cg-RX-API-DMAC7.html)
JO (1) JOP20190109B1 (cg-RX-API-DMAC7.html)
LT (1) LT3541807T (cg-RX-API-DMAC7.html)
MA (2) MA46866B1 (cg-RX-API-DMAC7.html)
MX (2) MX389459B (cg-RX-API-DMAC7.html)
MY (1) MY199386A (cg-RX-API-DMAC7.html)
NI (1) NI201900053A (cg-RX-API-DMAC7.html)
PE (1) PE20191239A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501068A1 (cg-RX-API-DMAC7.html)
PL (2) PL3541807T3 (cg-RX-API-DMAC7.html)
PT (1) PT3541807T (cg-RX-API-DMAC7.html)
RS (2) RS62665B1 (cg-RX-API-DMAC7.html)
SI (1) SI3541807T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202300494T1 (cg-RX-API-DMAC7.html)
TN (1) TN2019000151A1 (cg-RX-API-DMAC7.html)
UA (1) UA124585C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018093953A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903093B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
MY200738A (en) 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
MA52635A (fr) * 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
CA3106510A1 (en) * 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
SG11202108008PA (en) * 2019-01-25 2021-08-30 H Lundbeck As Methods of treating disease with magl inhibitors
BR112021013917A2 (pt) * 2019-11-15 2022-05-24 H Lundbeck As Forma cristalina de um inibidor de magl, composição farmacêutica e uso
WO2021214550A1 (en) * 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
WO2023213854A1 (en) 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2001225816B2 (en) 2000-12-18 2005-10-13 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
DE60325834D1 (de) 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
NZ627750A (en) * 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
EP2828253A1 (en) 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
WO2013159095A1 (en) 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
KR102396897B1 (ko) 2012-11-02 2022-05-13 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환의 치료를 위한 약제학적 조성물
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015164160A1 (en) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Similar Documents

Publication Publication Date Title
JP2022084717A5 (cg-RX-API-DMAC7.html)
JP2017527578A5 (cg-RX-API-DMAC7.html)
HRP20231697T1 (hr) Kristalni oblik magl inhibitora
JOP20190182A1 (ar) أسيتاميد n-] 4-فلور-5-]] (4s,2s)-2-ميثيل-4-](5-ميثيل-1،2،4-اوكسادايزول-3-يل)ميثوكسي[-1-بيبيرديل[ميثيل[ ثيازول-2-يل[ كمثبط oga
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
NZ597241A (en) Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
JP2015517981A5 (cg-RX-API-DMAC7.html)
IL291590B2 (en) Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
JP2012507535A5 (cg-RX-API-DMAC7.html)
JP2017534569A5 (cg-RX-API-DMAC7.html)
JP2018511587A5 (cg-RX-API-DMAC7.html)
JP2012516344A5 (cg-RX-API-DMAC7.html)
MX2010006260A (es) Composiciones orales de abt-263 para tratar cancer.
JP2009502795A5 (cg-RX-API-DMAC7.html)
NZ617334A (en) Cyclopropyl amine derivatives
JP2013510876A5 (cg-RX-API-DMAC7.html)
HRP20171908T1 (hr) Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora
JP2018168191A5 (cg-RX-API-DMAC7.html)
MX392634B (es) Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo
JP2018529770A5 (cg-RX-API-DMAC7.html)
JP2019510025A5 (cg-RX-API-DMAC7.html)
JP2009537542A5 (cg-RX-API-DMAC7.html)
JP2019532919A5 (cg-RX-API-DMAC7.html)
SI3102573T1 (en) SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7
HRP20201594T1 (hr) Novi kristalni oblik soli 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoksi-1h-pirol-3-il)-n- metilmetanamina